Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Hubert Köppler"'
Autor:
Rudolf, Weide, Jörg, Thomalla, Christoph, van Roye, Geothy, Chakupurakal, Jochen, Heymanns, Hubert, Köppler, Stefan, Feiten, Jörg-André, Nickel, Heinz, Schmidberger, Matthias, Theobald, Christoph, Lutz
Publikováno v:
GMS Journal for Medical Education; VOL: 39; DOC40 /20220915/
Aim: For several years now, medical students have also been taught general practice at academic medical teaching practices. Specialty practices have not yet been included in the curricular education. Since 1998, we have conducted a block seminar in h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8eae2802d5e5b2fad059be3941aad36
Autor:
C van Roye, R Weide, B Rendenbach, Stefan Feiten, Jochen Heymanns, Julia Lutschkin, Peter Ehscheidt, Hubert Köppler, Jörg Thomalla, Kristina Kleboth, U Braun, H-P Laubenstein, Vera Friesenhahn, K Hünermund, Oswald Burkhard, Geothy Chakupurakal
Publikováno v:
Cancer Research. 79:P1-16
Introduction: 18,000 women die due to metastatic breast cancer in Germany per year. Median survival is 20–28 months after diagnosis. The question we wanted to answer was whether survival has improved in routine care? Methods: Retrospective analysis
Autor:
Julia Lutschkin, Jochen Heymanns, Geothy Chakupurakal, R Weide, Kristina Kleboth, Hubert Köppler, Christoph van Roye, Jörg Thomalla, Stefan Feiten, Vera Friesenhahn
Publikováno v:
Leukemialymphoma. 61(3)
Seven hundred and twenty-four CLL-outpatients with a median age of 67 (35-92) were analyzed. Four hundred and twenty-seven (59%) were male, 297 (41%) female. At diagnosis 556 (77%) were in Binet stage A, 91 (13%) stage B and 36 (5%) stage C. Forty-si
Autor:
Rudolf Weide, C van Roye, Vera Friesenhahn, Jörg Thomalla, Hubert Köppler, Kristina Kleboth, Jochen Heymanns, Stefan Feiten
Publikováno v:
TumorDiagnostik & Therapie. 37:393-397
Hintergrund und Fragestellung | Bei chronischen lymphoproliferativen Erkrankungen wie indolenten Non-Hodgkin-Lymphomen (iNHL), chronischer lymphatischer Leukamie, follikularem Lymphom und multiplem Myelom sind Infektionen wichtige Komplikationen. Wir
Autor:
Vera Friesenhahn, J Dünnebacke, Stefan Feiten, Jörg Thomalla, R Weide, R. Meister, D Wey, C van Roye, Jochen Heymanns, Hubert Köppler
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76:557-563
Introduction: Currently, about 360 000 breast cancer patients who could, after completion of their primary therapy, take advantage of follow-up options are living in Germany. Up to now very little is known about the extent to which the available opti
Autor:
Vera Friesenhahn, R. Meister, Stefan Feiten, D Wey, Jörg Thomalla, Hubert Köppler, R Weide, Jochen Heymanns, C van Roye, J Dünnebacke
Publikováno v:
Cancer Research. 76:P4-10
Introduction: Breast cancer treatment leads to long-lasting impairments which, according to international guidelines, have to be identified and treated in follow-up care. It remains unclear how follow-up care is perceived by patients and if all needs
Autor:
Christoph van Roye, Jochen Heymanns, Stefan Feiten, Jörg Thomalla, Kristina Kleboth, Hubert Köppler, Vera Friesenhahn, Rudolf Weide
Publikováno v:
Leukemia & Lymphoma. 54:1640-1646
Bendamustine and bendamustine/rituximab combinations have shown high efficacy in relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent B-cell malignancies (non-Hodgkin lymphoma, NHL). No data exist about bendamustine retreatment after r
Autor:
D Wey, J Dünnebacke, Hubert Köppler, Stefan Feiten, Jörg Thomalla, R Weide, Jochen Heymanns, C van Roye
Publikováno v:
Cancer Research. 72:P2-11
Objectives: Evaluation of the subjectively experienced physical, psychological, social and job-related consequences of breast cancer. Methods: Standardized paper pencil interview of patients with the initial diagnosis of breast cancer who had their p
Autor:
Rudolf Schlag, Clemens-Martin Wendtner, Elisabeth Lange, Georg Köchling, Kirsten Fischer, Wolfram Klapper, Michael G. Kiehl, Sebastian Böttcher, Anna-Maria Fink, Hubert Köppler, Michael Gregor, Christian Maurer, Stephan Stilgenbauer, Torben Plesner, Jasmin Bahlo, Christoph Plöger, Raymonde Busch, Ursula Vehling-Kaiser, Harmut Döhner, Barbara Eichhorst, Michael Kneba, Marek Trneny, Martin Sökler, Gabor Kovacs, Karl-Anton Kreuzer, Michael Hallek
Publikováno v:
Eichhorst, B, Fink, A-M, Bahlo, J, Busch, R, Kovacs, G, Maurer, C, Lange, E, Köppler, H, Kiehl, M, Sökler, M, Schlag, R, Vehling-Kaiser, U, Köchling, G, Plöger, C, Gregor, M, Plesner, T, Trneny, M, Fischer, K, Döhner, H, Kneba, M, Wendtner, C-M, Klapper, W, Kreuzer, K-A, Stilgenbauer, S, Böttcher, S, Hallek, M & The German CLL Study group (GCLLSG) 2016, ' First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10) : an international, open-label, randomised, phase 3, non-inferiority trial ', The Lancet Oncology, vol. 17, no. 7, pp. 928-942 . https://doi.org/10.1016/S1470-2045(16)30051-1
BACKGROUND: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia. This international phase 3 study compared the efficacy and tolerance of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::757f379487ba123061e3e80fa89c7bc1
https://portal.findresearcher.sdu.dk/da/publications/e15d539d-e996-48a0-90ae-5d115577eb3e
https://portal.findresearcher.sdu.dk/da/publications/e15d539d-e996-48a0-90ae-5d115577eb3e
Autor:
Stefan Feiten, Hubert Köppler, Christoph van Roye, Vera Friesenhahn, Jochen Heymanns, Kristina Kleboth, Rudolf Weide, Jörg Thomalla
Publikováno v:
SpringerPlus
Due to the increase of oral agents nonadherence is an emerging challenge in cancer care. We evaluated how well different assessments match and how adherence could be measured in routine care. For this purpose patients suffering from metastatic solid